STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
Stat News • 5/27/2026
Summary
The FDA has extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug. Additionally, there is mention of an ADAP deal in Florida.
Advertisement
Lindy Score Breakdown (V4.2)
3h
Age
1
Sources
from cluster
2
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier97% (0.5^2/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Stat News • 1 day ago
STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
Stat News • Today
STAT+: ‘Are we just going to give up and die like every other generation?’
Stat News • Today
STAT+: Praise for FDA’s acting commissioner
Stat News • 1 day ago
STAT+: Where patients and hospitals disagree about AI
Stat News • Today
STAT+: $775 billion, $1.2 billion, and $38k
Stat News • 1 day ago
STAT+: An AI biotech CEO sets the record straight on AI drug development hype
Stat News • 1 day ago
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Stat News • 2 days ago
STAT+: How Kyle Diamantas defied expectations as he rose to lead the FDA
Stat News • 1 day ago
STAT+: How Stanford patients help expose ‘fault lines’ in health AI adoption
Stat News • Today